The present invention discloses the use of Avn Anthramides C (Avn C) as an
inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative
cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic
extracellular matrix (ECM) factors, notably
Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with
Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the
transcriptional activity state of SOX9, a key
regulator of
chondrogenesis. The disclosed invention shows significant improvements in
mRNA gene expression (ACAN, LRP1, SOX9),
cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the
secretion of
extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).